Joseph Edmonds
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Joseph Edmonds has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Brian Shuch
UCLA School of Medicine 14 Institute of Urologic Oncology Los Angeles, California
40 shared publications - Chana Sachs
Department of Pathology, University of California Los Angeles, Los Angeles, California. 4
40 shared publications - Dipti P. Sajed
Department of Pathology, University of California Los Angeles, Los Angeles, California. 4
40 shared publications - Hao Zeng
Department of Urology, West China Hospital of Sichuan University, Chengdu, Sichuan, China
40 shared publications - Jiayu Liang
Department of Urology, West China Hospital of Sichuan University, Chengdu, Sichuan, China
40 shared publications - Josh Spurrier
Department of Neurology, Yale University School of Medicine, New Haven, CT, USA
40 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion
NAPRT silencing confers sensitivity to NAMPTis in IDH1/2 mutant cancer cell line models.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion
NAPRT silencing confers sensitivity to NAMPTis in IDH1/2 mutant cancer cell line models.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion
Results from GO Pathway Analysis in FH-deficient cell lines.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion
Results from GO Pathway Analysis in FH-deficient cell lines.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion
Additional cell line validation.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion
Additional cell line validation.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 12 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion
Combination of FK866 and olaparib leads to sustained cell cycle arrest in G2.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 12 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion
Combination of FK866 and olaparib leads to sustained cell cycle arrest in G2.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion
Patient methylation and protein expression of NAPRT.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion
Patient methylation and protein expression of NAPRT.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 11 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion
Combination of PARPi and NAMPTi lead to unresolved double stranded breaks NAPRT silenced models.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 11 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion
Combination of PARPi and NAMPTi lead to unresolved double stranded breaks NAPRT silenced models.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion
Summary of statistics and data used to generate NAD+ pathway gene expression correlation plots.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion
Summary of statistics and data used to generate NAD+ pathway gene expression correlation plots.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 10 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion
NAMPTis and PARPis synergize in IDH1/2 NAPRT-deficient tumor models.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 10 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion
NAMPTis and PARPis synergize in IDH1/2 NAPRT-deficient tumor models.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion
Relationships between NAPRT, NAMPT, PARP, and QPRT expression in cancer cell lines.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion
Relationships between NAPRT, NAMPT, PARP, and QPRT expression in cancer cell lines.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion
Patient derived FH-deficient, NAPRT silenced cell line models are sensitive to multiple NAMPTis.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion
Patient derived FH-deficient, NAPRT silenced cell line models are sensitive to multiple NAMPTis.